Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 25;18(1):147.
doi: 10.1186/s12943-019-1086-z.

The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma

Ling Wei  1 , Xingwu Wang  1 , Liyan Lv  1 , Jibing Liu  1   2 , Huaixin Xing  1 , Yemei Song  1 , Mengyu Xie  1 , Tianshui Lei  1 , Nasha Zhang  3 , Ming Yang  4
Affiliations
Review

The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma

Ling Wei et al. Mol Cancer. .

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the second most lethal human cancer. A portion of patients with advanced HCC can significantly benefit from treatments with sorafenib, adriamycin, 5-fluorouracil and platinum drugs. However, most HCC patients eventually develop drug resistance, resulting in a poor prognosis. The mechanisms involved in HCC drug resistance are complex and inconclusive. Human transcripts without protein-coding potential are known as noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), long noncoding RNAs (lncRNAs) and circular RNA (circRNA). Accumulated evidences demonstrate that several deregulated miRNAs and lncRNAs are important regulators in the development of HCC drug resistance which elucidates their potential clinical implications. In this review, we summarized the detailed mechanisms by which miRNAs and lncRNAs affect HCC drug resistance. Multiple tumor-specific miRNAs and lncRNAs may serve as novel therapeutic targets and prognostic biomarkers for HCC.

Keywords: Drug resistance; Hepatocellular carcinoma; Long non-coding RNA; microRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A summary diagram of miRNAs and lncRNAs involved in the drug resistance of hepatocellular carcinoma (HCC). Various miRNAs and lncRNAs could participate in drug resistance of HCC by affecting cell apoptosis, proliferation, cell cycle, autophagy, epithelial-mesenchymal transition, and cancer stem cell via modulating the expression of downstream target genes
See this image and copyright information in PMC

References

    1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127. doi: 10.1056/NEJMra1001683. - DOI - PubMed
    1. Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer. 2013;2(3–4):345–364. doi: 10.1159/000343850. - DOI - PMC - PubMed
    1. Grem JL. 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investig New Drugs. 2000;18(4):299–313. doi: 10.1023/A:1006416410198. - DOI - PubMed
    1. Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis. 2015;19(2):421–432. doi: 10.1016/j.cld.2015.01.009. - DOI - PubMed
    1. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(7):408–424. doi: 10.1038/nrclinonc.2015.103. - DOI - PubMed

Publication types

MeSH terms